Avantor, Inc.: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on Apr 28, 2023 and accepted by EDGAR at Apr 28, 2023, 09:02 ET.
Management's discussion and analysis
As filed, 21,962 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
This discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results may differ materially from those contained in or implied by any forward-looking statements. See “Cautionary factors regarding forward-looking statements.”
Basis of presentation
This discussion should be read in conjunction with the accompanying condensed consolidated financial statements and notes. Pursuant to SEC rules for reports covering interim periods, we have prepared this discussion and analysis to enable you to assess material changes in our financial condition and results of operations since December 31, 2022, the date of our Annual Report. Therefore, we encourage you to read this discussion and analysis in conjunction with the Annual Report.
Overview
During the three months ended March 31, 2023, we recorded net sales of $1,780.3 million, net income of $121.5 million and Adjusted EBITDA of $346.2 million. Net sales decreased by 8.7%, which included a 6.6% decline in organic sales compared to the same period in 2022. See “Reconciliations of non-GAAP measures” for a reconciliation of net income to Adjusted EBITDA and “Results of operations” for a reconciliation of net sales growth to organic net sales growth.
Factors and current trends affecting our business and results of operations
The following updates the factors and current trends disclosed in the Annual Report. These updates could affect our performance and financial condition in future periods.
Our results continue to be impacted by the ongoing global coronavirus outbreak
Customer demand and required inventory levels continue to normalize in the transition from the COVID-19 pandemic, which has impacted our results for the three months ended March 31, 2023. For a discussion of the impact of the COVID-19 pandemic and associated economic disruptions, and the actual operational and financial impacts that we experienced through December 31, 2022, see “Part II—Item 7—Management's discussion and analysis of financial condition and results of operations” in the Annual Report. For additional discussion of the potential impact of the COVID-19 pandemic and associated economic disruptions on our results, see “The COVID-19 pandemic has adversely impacted, and continues to pose risks to, our business, operating results, cash flows and/or financial condition, the nature and extent of which could be material.” included in “Part I—Item 1A—Risk factors” in the Annual Report.
We have been impacted by supply chain constraints and inflationary pressures
We have experienced inventory fluctuations and build up at customers as a result of global supply chain disruptions and have experienced inflationary pressures across all of our cost categories. While we have implemented pricing and productivity measures to combat these pressures, they may continue to adversely impact our results.
Fluctuations in foreign currency rates impact our results
Our consolidated results of operations are comprised of many different functional currencies that translate into our U.S. Dollar reporting currency. The movement of the U.S. Dollar against those functional currencies, particularly the Euro, has caused significant variability in our results and may continue to do so in the future.
Key indicators of performance and financial condition
To evaluate our performance, we monitor a number of key indicators including certain non-GAAP financial measurements that we believe are useful to investors, creditors and others in assessing our performance. These measurements should not be considered in isolation or as a substitute for reported GAAP results because they may include or exclude certain items as compared to similar GAAP-based measurements, and such measurements may not be comparable to similarly-titled measurements reported by other companies. Rather, these measurements should be considered as an additional way of viewing aspects of our operations that provide a more complete understanding of our business.
The key indicators that we monitor are as follows:
- Net sales, gross margin, operating income and net income or loss. These measures are discussed in the section entitled “Results of operations”;
- Organic net sales growth, which is a non-GAAP measure discussed in the section entitled “Results of operations.” Organic net sales growth (decline) eliminates from our reported net sales the impact of changes in foreign currency exchange rates. We believe that this measurement is useful to investors as a way to measure and evaluate our underlying commercial operating performance consistently across our segments and the periods presented. This measurement is used by our management for the same reason. Reconciliations to the change in reported net sales, the most directly comparable GAAP financial measure, are included in the section entitled “Results of operations”;
- Adjusted EBITDA and Adjusted EBITDA margin, which are non-GAAP measures discussed in the section entitled “Results of operations.” Adjusted EBITDA is used by investors to measure and evaluate our operating performance exclusive of interest expense, income tax expense, depreciation, amortization and certain other adjustments. Adjusted EBITDA margin is Adjusted EBITDA divided by net sales as determined under GAAP. We believe that these measurements are useful to investors as a way to analyze the underlying trends in our business consistently across the periods presented. This measurement is used by our management for the same reason. A reconciliation of net income or loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA is included in the section entitled “Reconciliations of non-GAAP measures”;
- Cash flows from operating activities, which we discuss in the section entitled “Liquidity and capital resources—Historical cash flows”;
- Free cash flow, which is a non-GAAP measure, is equal to our cash flows from operating activities, plus acquisition-related costs paid in the period, less capital expenditures. We believe that this measurement is useful to investors as it provides a view on the Company’s ability to generate cash for use in financing or investing activities. This measurement is used by management for the same reason. A reconciliation of cash flows from operating activities, the most directly comparable GAAP financial measure, to free cash flow, is included in the section entitled “Liquidity and capital resources—Historical cash flows.”
Results of operations
We present results of operations in the same way that we manage our business, evaluate our performance and allocate our resources. We also provide discussion of net sales and Adjusted EBITDA by geographic segment based on customer location: Americas, Europe and AMEA. Corporate costs are managed on a standalone basis and not allocated to segments.
Executive summary
(dollars in millions)
| 2023 | Three months ended March 31, 2022 | Change | |
|---|---|---|---|
| Net sales | $1,780.3 | $1,950.4 | $(170.1) |
| Gross margin | 35.1% | 35.4% | (30) bps |
| Operating income | $231.2 | $307.0 | $(75.8) |
| Net income | 121.5 | 190.4 | (68.9) |
| Adjusted EBITDA | 346.2 | 423.1 | (76.9) |
| Adjusted EBITDA margin | 19.4% | 21.7% | (230) bps |
First quarter net sales decline was driven by a decline in all three regions primarily due to COVID-19 related headwinds as well as unfavorable foreign currency impact and inventory destocking. Unfavorable product mix along with manufacturing adjustments contributed to contraction in gross margin, while softness in sales volumes drove Adjusted EBITDA margin contraction.
Net Sales
Three months ended
(in millions)
| 2023 | Three months ended March 31, Net sales growth 2022 | Foreign currency impact | Reconciliation of net sales growth to organic net sales growth Organic net sales growth | ||
|---|---|---|---|---|---|
| Americas | $1,032.0 | $1,143.4 | $(111.4) | $(3.5) | $(107.9) |
| Europe | 630.2 | 680.4 | (50.2) | (32.8) | (17.4) |
| AMEA | 118.1 | 126.6 | (8.5) | (5.6) | (2.9) |
| Total | $1,780.3 | $1,950.4 | $(170.1) | $(41.9) | $(128.2) |
Net sales decreased $170.1 million or 8.7%, which included $41.9 million or 2.1% of unfavorable foreign currency impact. Organic net sales decreased by $128.2 million or 6.6% (declining 1.8% when excluding the impact of sales of COVID-19-related products in both periods, referred to herein as COVID-19 related headwinds or tailwinds).
In the Americas, net sales decreased $111.4 million or 9.7%, which included $3.5 million or 0.3% of unfavorable foreign currency impact. Organic net sales decreased by $107.9 million or 9.4% (3.7% excluding COVID-19 headwinds). Additional information on organic net sales growth by end market (with approximate percentage of total organic net sales for the region) is as follows:
- Biopharma (55%) — Sales declined double-digits, primarily due to the roll-off of COVID-19 revenues for vaccines, testing and PPE as well as destocking of lab consumables and single-use solutions.
- Healthcare (10%) — Sales declined double-digits as growth in our medical grade silicone business was offset by declines in COVID-19 related offerings for diagnostic testing and inventory destocking of lab products.
- *Education and government (15%) —*Sales declined low single-digits primarily due to lower sales of COVID-19 related offerings for diagnostic testing to university research customers and government accounts, as well as inventory destocking of lab products.
- Advanced technologies & applied materials (20%) — Sales decreased double-digits driven by softness in the demand for our semiconductor and electronic device offerings, as well as declines in COVID-19 related offerings for diagnostic testing and PPE.
In Europe, net sales decreased $50.2 million or 7.4%, which included $32.8 million or 4.8% of unfavorable foreign currency impact. Organic net sales decreased $17.4 million or 2.6% (increased 1.0% excluding COVID-19 headwinds). Additional information on organic net sales growth by end market (with approximate percentage of total organic net sales for the region) is as follows:
- Biopharma (50%) — Sales declined mid single-digits, primarily due to the roll-off of COVID-19 revenues for vaccines, testing and PPE as well as destocking of lab consumables and single-use solutions.
- Healthcare (10%) — Sales declined double-digits primarily due to the roll-off of COVID-19 revenues for testing and PPE as well as destocking of lab consumables.
- Education & government (10%) — Sales increased low single-digits driven by increased activity in academia and government labs, partially offset by the roll-off of COVID-19 revenues for testing and PPE as well as destocking of lab consumables.
- Advanced technologies & applied materials (30%) — Sales increased mid single-digits driven by resilient end market demand, partially offset by the roll-off of COVID-19 revenues for testing and PPE.
In AMEA, net sales decreased $8.5 million or 6.7%, which included $5.6 million or 4.4% of unfavorable foreign currency impact. Organic net sales decreased $2.9 million or 2.3% (increased 1.0% excluding COVID-19 headwinds). Additional information on organic net sales growth by end market (with approximate percentage of total organic net sales for the region) is as follows:
- Biopharma (50%) — Sales increased mid single-digits due to growth in sales of proprietary materials in biopharma production, partially offset by the roll-off of COVID-19 revenues associated with vaccine production.
- Advanced technologies & applied materials (40%) — Sales declined double-digits primarily driven by softness in our proprietary offerings into the semiconductor industry.
Gross margin
| 2023 | Three months ended March 31, 2022 | Change | |
|---|---|---|---|
| Gross margin | 35.1% | 35.4% | (30) bps |
Three months ended
Gross margin for the three months ended March 31, 2023 contracted by 30 basis points, resulting primarily from unfavorable product mix in our proprietary materials business and the impact of manufacturing variances, partially offset by lower freight and commercial excellence.
Operating income
(in millions)
| 2023 | Three months ended March 31, 2022 | Change | |
|---|---|---|---|
| Gross profit | $624.8 | $689.9 | $(65.1) |
| Operating expenses | 393.6 | 382.9 | 10.7 |
| Operating income | $231.2 | $307.0 | $(75.8) |
Three months ended
Operating income decreased primarily from lower gross profit, as previously discussed, as well as higher operating expenses driven by the accrual of a long-term retention incentive, inflation, and investments made to grow the business. These factors were partially offset by lower amortization expense.
Net income
(in millions)
| 2023 | Three months ended March 31, 2022 | Change | |
|---|---|---|---|
| Operating income | $231.2 | $307.0 | $(75.8) |
| Interest expense | (73.7) | (64.8) | (8.9) |
| Loss on extinguishment of debt | (2.3) | (1.8) | (0.5) |
| Other income, net | 0.6 | 1.4 | (0.8) |
| Income tax expense | (34.3) | (51.4) | 17.1 |
| Net income | $121.5 | $190.4 | $(68.9) |
Three months ended
Net income decreased primarily due to lower operating income, as previously discussed, as well as higher interest expense from rising interest rates on our variable-rate term loans. We also recorded a larger loss on the extinguishment of our debt resulting from higher optional prepayments of our term loans. These factors were partially offset by lower income tax expense due to lower income before income taxes.
Adjusted EBITDA and Adjusted EBITDA margin
For a reconciliation of Adjusted EBITDA to Net income, the most directly comparable measure under GAAP, see “Reconciliations of non-GAAP financial measures.”
(dollars in millions)
| 2023 Adjusted EBITDA: | Three months ended March 31, 2022 | Change | |
|---|---|---|---|
| Americas | $240.4 | $294.2 | $(53.8) |
| Europe | 121.7 | 143.4 | (21.7) |
| AMEA | 33.5 | 29.3 | 4.2 |
| Corporate | (49.4) | (43.8) | (5.6) |
| Total | $346.2 | $423.1 | $(76.9) |
| Adjusted EBITDA margin | 19.4% | 21.7% | (230) bps |
Three months ended
Adjusted EBITDA decreased $76.9 million or 18.2%, which included an unfavorable foreign currency translation impact of $10.0 million. The remaining decline was $66.9 million or 15.8%.
In the Americas, Adjusted EBITDA declined $53.8 million or 18.3%, or 18.0% when adjusted for unfavorable foreign currency translation impact. The decrease was driven by lower sales volume and unfavorable product mix primarily attributed to COVID-19 related headwinds, partially offset by commercial excellence.
In Europe, Adjusted EBITDA declined $21.7 million or 15.1%, or 9.8% when adjusted for unfavorable foreign currency translation impact. The decrease was driven by sales volume contraction, unfavorable product mix and additional investments in our workforce made over the course of 2022 and into 2023, partially offset by commercial excellence.
In AMEA, Adjusted EBITDA grew $4.2 million or 14.3%, or 19.5% when adjusted for unfavorable foreign currency translation impact. The increases driven by higher gross profit were partially offset by additional investments made in the region.
In Corporate, Adjusted EBITDA declined $5.6 million or 12.8% reflecting investments in our workforce made over the course of 2022 and into 2023 and increased stock-based compensation expense.
Reconciliations of non-GAAP financial measures
The following table presents the reconciliation of net income to Adjusted EBITDA:
(in millions)
| 2023 | Three months ended March 31, 2022 | |
|---|---|---|
| Net income | $121.5 | $190.4 |
| Interest expense | 73.7 | 64.8 |
| Income tax expense | 34.3 | 51.4 |
| Depreciation and amortization | 101.1 | 114.5 |
| Loss on extinguishment of debt | 2.3 | 1.8 |
| Net foreign currency (gain) loss from financing activities | (0.2) | 0.1 |
| Other stock-based compensation expense (benefit) | 0.1 | (1.3) |
| Integration-related expenses1 | 8.7 | 3.9 |
| Purchase accounting adjustments2 | — | (4.4) |
| Restructuring and severance charges3 | 4.7 | 1.9 |
| Adjusted EBITDA | $346.2 | $423.1 |
1. Represents non-recurring direct costs incurred with third parties and the accrual of a long-term retention incentive to integrate acquired companies. These expenses represent incremental costs and are unrelated to normal operations of our business. Integration expenses are incurred over a pre-defined integration period specific to each acquisition.
2. Represents the non-cash reduction of contingent consideration related to the Ritter acquisition.
3. Reflects the incremental expenses incurred in the period related to initiatives to increase profitability and productivity. Typical costs included in this caption are employee severance, site-related exit costs, and contract termination costs.
Liquidity and capital resources
We fund short-term cash requirements primarily from operating cash flows and credit facilities. Most of our long-term financing is from indebtedness. For the three months ended March 31, 2023, we generated $219.5 million of cash from operating activities, ended the quarter with $294.6 million of cash and cash equivalents and our availability under our credit facilities was $566.8 million. We have no debt repayments due in the next twelve months other than required term loan payments of $33.2 million and receivables facility borrowing of $287.3 million.
Liquidity
The following table presents our primary sources of liquidity:
(in millions)
| March 31, 2023 Receivables facility Revolving credit facility Total Unused availability under credit facilities: | |
|---|---|
| Capacity $352.8 $515.0 | $867.8 |
| Undrawn letters of credit outstanding (13.7) — | (13.7) |
| Outstanding borrowings (287.3) — | (287.3) |
| Unused availability $51.8 $515.0 | $566.8 |
| Cash and cash equivalents | 294.6 |
| Total liquidity | $861.4 |
Some of our credit line availability depends upon maintaining a sufficient borrowing base of eligible accounts receivable. We believe that we have sufficient capital resources to meet our liquidity needs.
Our debt agreements include representations and covenants that we consider usual and customary, and our receivables facility and senior secured credit facilities include a financial covenant that becomes applicable for periods in which we have drawn more than 35% of our revolving credit facility under the senior secured credit facilities. In this circumstance, we are not permitted to have combined borrowings on our senior secured credit facilities and secured notes in excess of a pro forma net leverage ratio, as defined in our credit agreements. As we had not drawn more than 35% of our revolving credit facility in this period, this covenant was not applicable at March 31, 2023.
At March 31, 2023, $273.7 million or 92.9% of our $294.6 million in cash and cash equivalents was held by our non-U.S. subsidiaries and may be subject to certain taxes upon repatriation, primarily where foreign withholding taxes apply.
Historical cash flows
The following table presents a summary of cash provided by (used in) various activities:
(in millions)
| 2023 Operating activities: | Three months ended March 31, 2022 | Change | |
|---|---|---|---|
| Net income | $121.5 | $190.4 | (68.9) |
| Non-cash items1 | 107.4 | 123.2 | (15.8) |
| Working capital changes2 | (39.8) | (108.1) | 68.3 |
| All other | 30.4 | (53.3) | 83.7 |
| Total | $219.5 | $152.2 | $67.3 |
| Investing activities | $(27.3) | $(39.5) | $12.2 |
| Cash paid for acquisitions, net of cash acquired | — | (15.3) | 15.3 |
| Capital expenditures | (28.0) | (24.5) | (3.5) |
| Financing activities | (275.0) | (127.2) | (147.8) |
1. Consists of typical non-cash charges including depreciation and amortization, stock based compensation expense, deferred income tax expense and others.
2. Includes changes to our accounts receivable, inventory, contract assets and accounts payable.
Cash flows from operating activities provided $67.3 million more cash in 2023 primarily due to improved working capital and lower payments for incentive compensation payments for fiscal year 2022 company performance. These items were partially offset by lower operating income.
Investing activities used $12.2 million less cash in 2023 due to the additional cash paid for the acquisition of Masterflex in the previous year. This item was offset by increased capital spending across the Company compared to the prior year.
Financing activities used $147.8 million more cash in 2023 primarily due to higher optional debt repayments on our term loans in comparison to 2022, offset by the absence of the payments for the dividends on the MCPS, which concluded in May of 2022.
Free cash flow
(in millions)
| 2023 | Three months ended March 31, 2022 | Change | |
|---|---|---|---|
| Net cash provided by operating activities | $219.5 | $152.2 | $67.3 |
| Capital expenditures | (28.0) | (24.5) | (3.5) |
| Free cash flow | $191.5 | $127.7 | $63.8 |
Free cash flow was $63.8 million higher in 2023 due to the changes in cash flows from operating activities noted above. These items were offset by increased capital spending across the Company in 2023, principally reflecting growth-related expansions in our global supply chain.
Indebtedness
For information about our indebtedness, refer to the section entitled “Liquidity” and note 8 to our unaudited condensed consolidated financial statements included in Part I, Item 1 — “Financial statements.”
New accounting standards
There were no new accounting standards that we expect to have a material impact on our financial position or results of operations upon adoption.
Controls and procedures
As filed, 1,007 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Management’s evaluation of disclosure controls and procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2023, the design and operation of our disclosure controls and procedures were effective to accomplish their objectives at the reasonable assurance level.
Changes in internal control over financial reporting
There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) during the fiscal quarter ended March 31, 2023, that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.
Risk factors
As filed, 316 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
For information regarding factors that could affect the Company's results of operations, financial condition and liquidity, see the risk factors discussed in Part I, Item 1A “Risk Factors” in our Annual Report. There have been no material changes to the risk factors disclosed in Part I—Item 1A of the Annual Report.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-01-01 to 2023-03-31 | $1.78bn | us-gaap:Revenues |
| Cost of revenue | 3 months2023-01-01 to 2023-03-31 | $1.16bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-01-01 to 2023-03-31 | $624.8m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2023-01-01 to 2023-03-31 | $393.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-01-01 to 2023-03-31 | $231.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-01-01 to 2023-03-31 | $73.7m | us-gaap:InterestExpense |
| Income tax | 3 months2023-01-01 to 2023-03-31 | $34.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-01-01 to 2023-03-31 | $121.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-01-01 to 2023-03-31 | $0.18 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-01-01 to 2023-03-31 | $0.18 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-01-01 to 2023-03-31 | 678,100,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-01-01 to 2023-03-31 | $219.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-01-01 to 2023-03-31 | $28.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-03-31 | $294.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $2.63bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $13.40bn | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $1.67bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $8.40bn | us-gaap:Liabilities |
| Long-term debt | At period end2023-03-31 | $5.74bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2023-03-31 | $325.2m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2023-03-31 | $4.99bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001722482-23-000100. Last ingested by Listed: Nov 13, 2026, 16:45 ET. Listed shows no prices and gives no investment advice.